Guidance
Evidence-based recommendations on SecurAcath for securing percutaneous catheters.
In August 2022, we updated this guidance to reflect 2021 costs and revise cost-saving estimates. These are marked [2022]. Details of the changes are explained in the review decision from July 2022.
NICE has published a medtech innovation briefing on SecurAcath for an emerging indication (securing cerebrospinal fluid catheters) for which the evidence and use are still developing.
Implementation
NICE has developed tools and resources, in association with relevant stakeholders, to help organisations put this guidance into practice.
Is this guidance up to date?
Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.
Guidance development process
How we develop NICE medical technologies guidance
NICE medical technologies guidance addresses specific technologies notified to NICE by sponsors. The ‘case for adoption’ is based on the claimed advantages of introducing the specific technology compared with current management of the condition. This case is reviewed against the evidence submitted and expert advice. If the case for adopting the technology is supported, then the technology has been found to offer advantages to patients and the NHS. The specific recommendations on individual technologies are not intended to limit use of other relevant technologies which may offer similar advantages.